Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis

Journal of Infectious Diseases

Volumn 179, Issue 6, 1999, Pages 1477-1484

  Han, Yongmoon ^a   Ulrich, Melinda A ^a   Cutler, Jim E ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BOVINE SERUM ALBUMIN; MANNAN; SERUM PROTECTIVE FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONJUGATION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; VACCINATION;

ANIMALS; ANTIBODIES, FUNGAL; ANTIBODY SPECIFICITY; CANDIDA ALBICANS; CANDIDIASIS; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; FUNGAL VACCINES; IMMUNIZATION, PASSIVE; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOSOMES; MANNANS; MICE; MICE, INBRED BALB C; VACCINATION;

EID: 0032995552     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314779     Document Type: Article

References (42)

1. 1. Edwards JE. Invasive Candida infections: evolution of a fungal pathogen. N Engl J Med 1991;324:1060-2.
2. 2. Bodey GP. The emergence of fungi as major hospital pathogens. J Hosp Infect 1988;11(Suppl A):411-26.
3. 3. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin b and a review of the literature. Clin Infect Dis 1996;23:964-72.
4. 4. Edwards JE Jr, Filler SG. Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients. Clin Infect Dis 1992;14(Suppl 1);S106-S13.
5. 5. Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178:203-11.
6. 6. Nyirjesy P, Seeney SM, Grody MHT, Jordan CA, Buckley HR. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol 1995;173: 820-3.
7. 7. Edwards JE, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997;25:43-59.
8. 8. Wingard JR. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin Infect Dis 1994;19(Suppl 1):S49-S53.
9. 9. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
10. 10. White A, Goetz MB. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review. Clin Infect Dis 1994;19:687-92.
11. 11. Odds FC. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother 1993;31:463-71.
12. 12. Banerjee U, Mohapatra LN, Kumar R. Role of antibody in defense against murine candidosis. Indian J Med Res 1984;79:760-5.
13. 13. Hector RF, Domer JE, Carrow EW. Immune responses to Candida albicans in genetically distinct mice. Infect Immun 1982;38:1020-8.
14. 14. Wagner RD, Vazquez-Torres A, Jones-Carson J, Warner T, Balish E. B cell knockout mice are resistant to mucosal and systemic candidiasis of endogenous origin but susceptible to experimental systemic candidiasis. J Infect Dis 1996;174:589-97.
15. 15. Berger M, Kirkpatrick CH, Goldsmith PK, Gallin JI. IgE antibodies to Staphylococcus aureus and Candida albicans in patients with the syndrome of hyperimmunoglobulin E and recurrent infections. J Immunol 1980; 125:2437-43.
16. 16. van Deventer AJM, Goessens WHF, van Zeijl JH, Mouton JW, Michel MF, Verbrugh HA. Kinectics of anti-mannan antibodies useful in confirming invasive candidiasis in immunocompromised patients. Microbiol Immunol 1996;40:125-31.
17. 17. Odds FC. Candida and candidosis. London: Bailliere Tindall, 1988.
18. 18. Cassone A, Boccanera M, Adriani D, Santoni G, De Bernardis F. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun 1995;63:2619-24.
19. 19. Costantino PJ, Franklyn KM, Gare NF, Warmington JR. Production of antibodies to antigens of Candida albicans in CBA/H mice. Infect Immun 1994;62:1400-5.
20. 20. Man Y, Cutler JE. Antibody response that protects against disseminated candidiasis. Infect Immun 1995;63:2714-9.
21. 21. Matthews RC. Pathogenicity determinants of Candida albicans: potential targets for immunotherapy? Microbiology 1994;140:1505-11.
22. 22. Mourad S, Friedman L. Active immunization of mice against Candida albicans. Proc Soc Exp Biol Med 1961;106:570-2.
23. 23. Mourad S, Friedman L. Passive immunization of mice against Candida albicans. Sabouraudia 1968;6:103-5.
24. 24. Tavares D, Ferreira P, Vilanova M, Videira A, Arala-Chaves M. Immunoprotection against systemic candidiasis in mice. Int Immunol 1995;7: 785-96.
25. 25. Cassone A, Conti S, De Bernardis F, Polonelli L. Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature? Immunol Today 1997;18:164-9.
26. 26. Han Y, Morrison RP, Cutler JE. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998;66:5771-6.
27. 27. Han Y, Cutler JE. Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. J Infect Dis 1997;175:1169-75.
28. 28. Claassen E, van Rooijen N. Preparation and characteristics of dichloromethylene diphosphonate containing liposomes. J Microencapsul 1986;3: 109-14.
29. 29. Kanbe T, Cutler JE. Evidence for adhesin activity in the acid-stable moiety of the phosphomannoprotein complex of Candida albicans. Infect Immun 1994;62:1662-8.
30. 30. Kanbe T, Han Y, Redgrave B, Riesselman MH, Cutler JE. Evidence that mannans of Candida albicans are responsible for adherence of yeast forms to spleen and lymph node tissue. Infect Immun 1993;61:2578-84.
31. 31. Schneerson R, Robbins JB, Parke JC, et al. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun 1986;52:519-28
32. 32. Dubois M, Gillis KA, Hamilton JK, Rebers PA, Smith F. Colorimetric method for determination of sugars and related substances. Analyt Chem 1956;28:350-6.
33. 33. Han Y, Kanbe T, Cherniak R, Cutler JE. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect Immun 1997;65:4100-7.
34. 34. Kapitany RA, Zebrowski EJ. A high resolution PAS stain for polyacrylamide gel electrophoresis. Anal Biochem 1973;56:361-9.
35. 35. Qian Q, Jutila MA, van Rooijen N, Cutler JE. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J Immunol 1994;152:5000-8.
36. 36. Li RK, Cutler JE. Chemical definition of an epitope/adhesin molecule on Candida albicans. J Biol Chem 1993;268:18293-9.
37. 37. Charpentier C, Fontanges R. Mise en evidence du caractere haptenique des peptidomannanes de deux levures: saccharomyces oviformis et candida mycoderma. Mycopathologia 1977;61:143-50.
38. 38. Van Regenmortel MHV, Briand JP, Muller S, Plaue S. Peptide-carrier conjugation. In: Burdon RH, Van Knippenberg PH, eds. Lab Tech Biochem Molecular Biol New York: Elsevier Science, 1988;19:95-130.
39. 39. Harlow E, Lane D. Antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1988:77-153.
40. 40. Casadevall A, Mukherjee J, Devi SJN, Schneerson R, Robbins JB, Scharff MD. Antibodies elicited by a Cryptococcus neoformans - tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis 1992;165:1086-93.
41. 41. Paoletti LC, Wessels MR, Michon F, DiFabio J, Jennings HJ, Kasper DL. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 1992;60:4009-14.
42. 42. Fu Y, Filler SG, Spellberg BJ, et al. Cloning and characterization of CAD1/ AAF1, a gene from Candida albicans that induces adherence to endothelial cells after expression in Saccharomyces cerevisiae. Infect Immun 1998;66: 2078-84.